Affordable Access

Publisher Website

Biomarkers:What is Their Benefit in the Identification of Infection, Severity Assessment, and Management of Community-acquired Pneumonia?

Authors
Journal
Infectious Disease Clinics of North America
0891-5520
Publisher
Elsevier
Volume
27
Issue
1
Identifiers
DOI: 10.1016/j.idc.2012.11.003
Keywords
  • Biomarkers
  • Procalcitonin
  • C-Reactive Protein
  • Duration Of Therapy
  • Community-Acquired Pneumonia
  • Severity Of Illness
Disciplines
  • Medicine

Abstract

Biomarkers have been proposed as tools that can guide the management of patients with community-acquired pneumonia, providing information that supplements the usually available clinical data. Among the available biomarkers, procalcitonin has been studied extensively and seems promising for several purposes. The use of biomarkers needs further study, to validate their utility in daily practice, especially given the limitations of the current tools for identifying the need for antibiotic therapy in patients with influenza and secondary bacterial pneumonia, in patients with aspiration syndromes, and in those infected with atypical pathogens.

There are no comments yet on this publication. Be the first to share your thoughts.